Global Boron Neutron Capture Therapy (BNCT) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Boron Neutron Capture Therapy (BNCT) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Boron neutron capture therapy (BNCT) is a non-invasive therapeutic technique used to treat invasive malignancies. By selectively concentrating boron compounds in tumor cells, and then using neutrons to generate high-energy alpha particles to destroy cells within the tumor without harming cells in surrounding tissues, it is a rapidly developing new generation of precision cancer treatment technology.

In a BNCT, neutrons must be delivered at a high flow rate (kerma), at the correct energy, and with minimal contamination. Neutrons for epithermal radiation are produced by nuclear reactors and ABNS. Because of the high cost, large footprint, difficulty of retrofitting, and high O&M costs, most nuclear reactors commissioned in the 1950s are closed today, are on the verge of closure, or are minimally active in the BNCT test, with only a few still open. Currently, the only hope for large-scale clinical trials is the use of accelerator-based neutron sources to produce qualified neutron beams for promotion to general hospitals for BNCT treatment of tumors. The report focuses on accelerator-based BNCT treatments.

Market Overview:

The latest research study on the global Boron Neutron Capture Therapy (BNCT) market finds that the global Boron Neutron Capture Therapy (BNCT) market reached a value of USD 11.37 million in 2022. It’s expected that the market will achieve USD 265.26 million by 2028, exhibiting a CAGR of 69.04% during the forecast period.

Region Overview:

BNCT can inhibit the effect on normal tissue compared with traditional chemoradiotherapy
BNCT has a high therapeutic effect. Compared with traditional radiotherapy and chemotherapy, the range of BNCT is limited to a single-cell range. This cell-level treatment can reduce damage to normal tissues and greatly reduce side effects. Moreover, the treatment course is short, and only 1-2 times of irradiation are needed for the full treatment course of highly developed BNCT, which is much lower than the existing radiotherapy. Usually, when radiation is given, the area around the tumor is left with a margin, taking-into account the areas where cancer cells may infiltrate and the body's movement during treatment. As a result, normal tissue is also damaged by radiation. However, BNCT only precisely damages cells that have absorbed boron drugs, so it can selectively destroy cancer cells and suppress the impact on normal tissues as much as possible. That is to say, through positron labeling technology, BNCT can conduct a differentiated evaluation of boron-containing drugs for individuals, predict the prognosis, form individualized diagnosis and treatment plans, and achieve precise treatment.

Wide range of applications and huge market development potential

Boron neutron capture therapy technology is an emerging and rapidly developing precision diagnosis and treatment technology in the field of international tumor treatment in recent years. It is called the fifth therapy after surgery, traditional radiotherapy, anticancer drugs, and immunotherapy by the Japanese medical community. invasive, locally metastatic tumors have outstanding clinical advantages and have been clinically proven to have significant and reliable curative effects on recurrent head and neck cancer, malignant brain tumors, melanoma skin cancer, osteosarcoma, breast cancer, and other solid tumors. In the future, with the continuous improvement of neutron quality by new neutron source technology and the emergence of more new specific targeted molecular drugs, the indications of BNCT will be further expanded, and it is expected to quickly become the first-line method for the treatment of malignant tumors. Moreover, due to certain market regulations and technical barriers in the boron neutron capture therapy industry, there are currently very few players in the world, the competition pattern is good, and the market development potential is huge.

Company Overview:

Sumitomo Heavy Industries, Ltd. Obtains Medical Device Approval for Manufacturing and Sales of Accelerator Based BNCT System and the Dose Calculation Program in Japan
March 12, 2020
TOKYO--(BUSINESS WIRE) --Sumitomo Heavy Industries, Ltd. (TOKYO: 6302) (President: Shinji Shimomura, referred as SHI hereinafter) has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using an accelerator (cyclotron), targeting carcinoma of the head and neck region in collaboration with STELLA PHARMA CORPORATION (President: Tomoyuki Asano). And SHI has applied the system for new medical device approval on 11th October, 2019. Today, they would like to announce that Sumitomo Heavy Industries, Ltd. obtains new medical device approval for manufacturing and sales of accelerator based BNCT system (NeuCureTM System) and the dose calculation program (NeuCureTM Dose Engine) from Japanese Ministry of Health, Labor and Welfare. These are the world’s first medical devices for BNCT.

Segmentation Overview:

Among different product types, Epithermal Beam segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Extracranial Tumor segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Boron Neutron Capture Therapy (BNCT) market covered in Chapter 3:

Neutron Therapeutics
Cancer Intelligence Care Systems, Inc
TAE Life Sciences
Neuboron Medtech
Sumitomo Heavy Industries Ltd

In Chapter 4 and Chapter 14.2, on the basis of types, the Boron Neutron Capture Therapy (BNCT) market from 2018 to 2029 is primarily split into:

Thermal Beam
Epithermal Beam

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Boron Neutron Capture Therapy (BNCT) market from 2018 to 2029 covers:

Brain Tumor
Extracranial Tumor

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)